Tech Company Financing Transactions
Ceptaris Therapeutics Funding Round
Ceptaris Therapeutics secured a $15 million funding round on 2/21/2012. Investors included Oxford Finance and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
2/21/2012
Transaction Type
Debt
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will be used for ongoing operational expenses and preparation for commercialization of its investigational drug, mechlorethamine gel. Ceptaris received $7.5 million at closing and has access to the remaining $7.5 million if the NDA is approved by the FDA.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Tullman
Chief Medical Officer
Jeffrey Wilkins
Chief Operating Officer
Douglas Gssl
VP - Bus. Development
Evan Dick
VP - General Counsel
Kamil Ali-Jackson
VP - Operations
Jeffrey Shaver
VP - R & D
Timothy Henkel
Browse more venture capital transactions:
Prev: 2/21/2012: Comet Solutions venture capital transaction
Next: 2/21/2012: Avedro venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs